Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Cardiology

Stages and Progression of Hypertensive Heart Disease

At a Glance

Hypertensive heart disease often develops gradually: high blood pressure can thicken and stiffen the heart before symptoms appear, and some people later develop heart failure. Early treatment, organ-damage screening, and personalized risk assessment can slow or partly reverse these changes.

Hypertensive heart disease (HHD) is not a single event, but a clinical continuum—a progression of physical changes that occurs over years or decades [1][2]. Understanding where you sit on this timeline is essential because it helps your care team determine how aggressively to manage your blood pressure to prevent complications [3][4].

The Stages of Progression

For many patients, HHD follows a general path. While not everyone will move through every stage (and it is not an inevitable ladder), the general progression involves the heart moving from “compensated” (working harder but still functioning) to “decompensated” (struggling to keep up) [1][2]:

  1. Hypertension: The starting point. The heart is healthy, but it is beginning to feel the stress of pushing against high pressure [5].
  2. Left Ventricular Hypertrophy (LVH): The heart muscle thickens (concentric remodeling involves increased wall thickness, while LVH involves increased mass) to handle the workload. At this stage, you likely feel normal, but your heart is physically changing [1][6].
  3. Diastolic Dysfunction: The thickened muscle becomes stiff and develops microscopic scarring (fibrosis). The heart can still pump blood out, but it can no longer relax and fill with blood properly [1][7].
  4. Heart Failure with Preserved Ejection Fraction (HFpEF): If the stiffness becomes severe enough to cause clinical symptoms like shortness of breath and fluid retention, HFpEF may be diagnosed. Your ejection fraction is still “normal,” but the heart is failing to fill adequately [1][8]. LVH or early diastolic dysfunction alone does not mean you have heart failure.
  5. Heart Failure with Reduced Ejection Fraction (HFrEF): In some patients, the heart eventually tires and begins to stretch out and weaken. The ejection fraction drops [2][9]. This is not an inevitable final stage; HFrEF can also arise from ischemia or other myocardial diseases.

Research indicates that among patients in a specific study who had both LVH and HFpEF, about 26.8% saw their ejection fraction drop below 50% within five years [10]. (Note: This is a cohort statistic, not your individual prognosis. Progression depends heavily on treatment and comorbidities).

Hypertension-Mediated Organ Damage (HMOD)

Medical guidelines now look beyond just the numbers on a blood pressure cuff. Doctors assess Hypertension-Mediated Organ Damage (HMOD)—physical evidence that high pressure has already injured your body [11][12]. HMOD is a powerful “risk reclassifier,” meaning that if you have it, your risk for a cardiovascular event is significantly higher [12][13].

Common markers of HMOD include [11][12]:

  • The Heart: Thickening (LVH) seen on an EKG or echocardiogram.
  • The Kidneys: Protein leaking into the urine (albuminuria) or a decrease in kidney filtration (reduced eGFR).
  • The Eyes: Damage to the small blood vessels in the retina (retinopathy).
  • The Arteries: Stiffening or premature plaque buildup in the neck or leg arteries.

The more “sites” of HMOD you have, the higher your risk. One study found that patients with HMOD in three different organ systems had nearly four times the rate of major cardiovascular events compared to those with no organ damage [14]. (Again, this is population data and must be interpreted in your clinical context).

Assessing Your Risk: The 2025 Guidelines

The 2025 AHA/ACC guidelines have introduced a more comprehensive way to calculate your risk using the PREVENT equations [4][15]. Instead of just looking at the risk of a heart attack, this new tool calculates your 10-year total cardiovascular disease risk, which specifically includes your risk of developing heart failure [16][15].

  • Treatment Threshold: If you have “Stage 1” hypertension (130-139 / 80-89 mmHg) and your calculated 10-year total risk is 7.5% or higher, guidelines often recommend starting medication alongside lifestyle changes [16][4]. However, this threshold must be applied carefully by your doctor based on your specific health profile, age, and comorbidities.
  • Comprehensive Screening: The latest consensus recommends that adults with hypertension receive basic screening for organ damage, including an EKG and kidney lab tests (urine albumin and serum creatinine) [11][17].

By identifying HHD in its earlier stages, you and your doctor can take steps to “reverse” some of the remodeling and significantly lower your future risk [18][19].

Common questions in this guide

What are the stages of hypertensive heart disease?
It often begins with high blood pressure, followed by thickening of the heart muscle and difficulty relaxing and filling. Some people develop heart failure with a normal pumping percentage, while others may later develop a reduced pumping percentage. Not everyone moves through every stage, and reduced pumping function is not inevitable.
Does left ventricular hypertrophy mean that I have heart failure?
No. Left ventricular hypertrophy means that the main pumping chamber has become thicker, often without causing symptoms. It can make the heart stiff and increase the risk of heart failure, but thickening alone is not a diagnosis of heart failure.
What does hypertension-mediated organ damage mean?
Hypertension-mediated organ damage means there is physical evidence that high blood pressure has affected organs such as the heart, kidneys, eyes, or arteries. Finding damage in more than one organ system is associated with a higher risk of cardiovascular problems.
How do doctors check whether hypertensive heart disease is progressing?
Doctors may use an EKG or echocardiogram to look for heart thickening and changes in function. Kidney assessment can include urine albumin and blood creatinine tests, with kidney filtration estimated from the results. The PREVENT equations can also estimate 10-year total cardiovascular risk, including heart failure risk.
Can early hypertensive heart disease be slowed or partly reversed?
Controlling blood pressure early can slow progression and may improve some of the heart's structural changes. Treatment commonly combines blood pressure medicine with lifestyle changes, tailored to your other health conditions and overall cardiovascular risk.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my current 'stage' of hypertension-mediated organ damage (HMOD), and which organs are affected?
  2. 2.What is my 10-year total cardiovascular disease risk according to the PREVENT equations?
  3. 3.Does my heart currently show 'concentric' thickening or 'eccentric' stretching, and why does that matter for my risk of heart failure?
  4. 4.If I have HFpEF (preserved ejection fraction), how often should we check my ejection fraction to watch for a shift toward HFrEF?
  5. 5.Does my urine albumin-creatinine ratio (UACR) suggest that my kidneys are being affected by my blood pressure?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    The Transition From Hypertension to Heart Failure: Contemporary Update.

    Messerli FH, Rimoldi SF, Bangalore S

    JACC. Heart failure 2017; (5(8)):543-551 doi:10.1016/j.jchf.2017.04.012.

    PMID: 28711447
  2. 2

    The Evolution from Hypertension to Heart Failure.

    Sorrentino MJ

    Heart failure clinics 2019; (15(4)):447-453 doi:10.1016/j.hfc.2019.06.005.

    PMID: 31472880
  3. 3

    Stable but Progressive Nature of Heart Failure: Considerations for Primary Care Physicians.

    Anand I

    American journal of cardiovascular drugs : drugs, devices, and other interventions 2018; (18(5)):333-345 doi:10.1007/s40256-018-0277-0.

    PMID: 29761293
  4. 4

    Using PREVENT Equations to Compare Intensive vs Standard Systolic Blood Pressure Control for Primary Prevention in SPRINT.

    Derington CG, Berchie RO, Greene T, et al.

    Journal of the American College of Cardiology 2025; (86(17)):1437-1448 doi:10.1016/j.jacc.2025.07.037.

    PMID: 41125318
  5. 5

    Association of Blood Pressure Classification Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Risk of Heart Failure and Atrial Fibrillation.

    Kaneko H, Yano Y, Itoh H, et al.

    Circulation 2021; (143(23)):2244-2253 doi:10.1161/CIRCULATIONAHA.120.052624.

    PMID: 33886370
  6. 6

    Introducing the Concept of Hypertensive Heart Disease to Improve Hypertensive Left Ventricular Hypertrophy.

    Koracevic G, Stojanovic M, Zdravkovic M, et al.

    Current vascular pharmacology 2025; (23(4)):247-254 doi:10.2174/0115701611351415241212092014.

    PMID: 39851109
  7. 7

    Evaluation of Left Atrial Function in Patients with Hypertensive Heart Disease and Preserved Ejection Fraction Using Real-Time, Three- Dimensional Speckle Tracking Imaging.

    He X, Yang X, Guo P, Ran H

    Kardiologiia 2025; (65(8)):63-70 doi:10.18087/cardio.2025.8.n2856.

    PMID: 40927936
  8. 8

    Relationship Between Focal and Diffuse Fibrosis Assessed by CMR and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.

    Kanagala P, Cheng ASH, Singh A, et al.

    JACC. Cardiovascular imaging 2019; (12(11 Pt 2)):2291-2301 doi:10.1016/j.jcmg.2018.11.031.

    PMID: 30772227
  9. 9

    Coronary microvascular dysfunction in hypertrophy and heart failure.

    Camici PG, Tschöpe C, Di Carli MF, et al.

    Cardiovascular research 2020; (116(4)):806-816 doi:10.1093/cvr/cvaa023.

    PMID: 31999329
  10. 10

    Left ventricular geometry transition in hypertensive patients with heart failure with preserved ejection fraction.

    Guan P, Gu J, Song ZP, et al.

    ESC heart failure 2021; (8(4)):2784-2790 doi:10.1002/ehf2.13349.

    PMID: 33931949
  11. 11

    Selecting the optimal method for assessment of hypertension-mediated organ damage: a personalized approach.

    Gerdts E, Benetos A, Bruno RM, et al.

    European journal of preventive cardiology 2026; (33(7)):1021-1032 doi:10.1093/eurjpc/zwag052.

    PMID: 41603527
  12. 12

    Hypertension-Mediated Organ Damage: Prevalence, Correlates, and Prognosis in the Community.

    Vasan RS, Song RJ, Xanthakis V, et al.

    Hypertension (Dallas, Tex. : 1979) 2022; (79(3)):505-515 doi:10.1161/HYPERTENSIONAHA.121.18502.

    PMID: 35138872
  13. 13

    Interrelations Between Arterial Stiffness, Target Organ Damage, and Cardiovascular Disease Outcomes.

    Vasan RS, Short MI, Niiranen TJ, et al.

    Journal of the American Heart Association 2019; (8(14)):e012141 doi:10.1161/JAHA.119.012141.

    PMID: 31303106
  14. 14

    Hypertension-mediated organ damage involving multiple sites is an independent risk factor for cardiovascular events.

    Lembo M, Pacella D, Manzi MV, et al.

    European heart journal open 2023; (3(5)):oead102 doi:10.1093/ehjopen/oead102.

    PMID: 37881599
  15. 15

    Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals.

    Neuen BL, Major RW, Grams ME, et al.

    Nature medicine 2026; (32(7)):2629-2638 doi:10.1038/s41591-026-04437-z.

    PMID: 42086979
  16. 16

    Use of Risk Assessment to Guide Decision-Making for Blood Pressure Management in the Primary Prevention of Cardiovascular Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.

    Khan SS, Abdalla M, Bello NA, et al.

    Circulation 2025; (152(11)):e219-e238 doi:10.1161/CIR.0000000000001355.

    PMID: 40875802
  17. 17

    From Structural to Functional Hypertension Mediated Target Organ Damage-A Long Way to Heart Failure with Preserved Ejection Fraction.

    Mancusi C, Lembo M, Manzi MV, et al.

    Journal of clinical medicine 2022; (11(18)) doi:10.3390/jcm11185377.

    PMID: 36143024
  18. 18

    Is Left Ventricular Hypertrophy a Valid Therapeutic Target?

    Brooks JE, Soliman EZ, Upadhya B

    Current hypertension reports 2019; (21(6)):47 doi:10.1007/s11906-019-0952-9.

    PMID: 31111289
  19. 19

    Sensitive marker for evaluation of hypertensive heart disease: extracellular volume and myocardial strain.

    Niu J, Zeng M, Wang Y, et al.

    BMC cardiovascular disorders 2020; (20(1)):292 doi:10.1186/s12872-020-01553-7.

    PMID: 32539749

This page is for informational purposes only and does not replace professional medical advice. Ask your healthcare provider to interpret your blood pressure, heart tests, organ-damage findings, and individual cardiovascular risk.

Get notified when new evidence is published on hypertensive heart disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.